IV NAD+ and Parkinson’s Disease

Parkinson’s disease is a degenerative nerve disorder that severely affects motor movement. There is no cure for Parkinson’s disease, but patients can be treated with medications that may help alleviate some of the symptoms. Symptoms of Parkinson’s disease include tremor, slowed movement (bradykinesia), rigid muscles, impaired balance, impaired autonomic movements (smiling, blinking or arm motion while walking), impaired speech and writing.

 

The causes of Parkinson’s disease include specific gene mutations and environmental toxins. Changes in the brain occur overtime. Parkinson’s disease involves impairment in the area of the brain known as the substantia nigra. The substantia nigra is involved with the neurotransmitter dopamine and Parkinson’s disease affects dopamine-producing neurons of the brain. These nerve cells in the basal ganglia and substantia nigra are responsible for messages affecting body movement and other brain functions such as speech.

 

Complications of Parkinson’s disease may include difficulty walking, cognitive impairment, depression and emotional difficulties, swallowing problems, sleep disorders, bladder problems, fatigue, reduced sense of smell, hallucinations and bowel changes (mostly constipation).

 

Parkinson’s disease affects for than 1 million people in the United States and 7-10 million worldwide. Every year greater than 60,000 new cases of Parkinson’s disease are diagnosed. It affects men 50% more of the time compared to women. Most cases are diagnosed in people in their 60s.

 

Recent research with NAD+ therapy shows promising results in many brain disorders including Parkinson’s disease.  Glutathione has also showed promise in treating Parkinson’s disease and improving movement and rigidity (please see Glutathione section for more information)

 

NAD and Cellular Function in Parkinson’s Disease

As discussed before, the mitochondria are known as the energy center or powerhouse of the cell. There are thousands of mitochondria in each cell. Some research suggested that damaged mitochondria may have a role in Parkinson’s disease.  Mitochondrial dysfunction is associated with aging and the decline of the all-too-important compound NAD+.

 

Parkinson’s patients may suffer a decline in NAD and an animal study showed improvement in cell energy balance when given vitamin B3 which is a precursor of NAD. Healthy mitochondria formed and the specimens had better energy production.

 

Sirtuins and Parkinson’s Disease

Sirtuins are proteins involved in regulating cell processes such as aging and death of cells. Sirtuins regulate cellular metabolic signaling. Sirtuins are though to have a protective role in inflammatory processes of the brain and body such as those seen in neurodegenerative disorders. When NAD+levels fluctuate such as they do in disease this affects the level and expression of Sirtuins.

 

Since levels of NAD+ are most likely reduced in Parkinson’s disease, it may help to replenish the system intravenously with NAD+. This in turn may lead to healthy expression of Sirtuins and mitochondria. Therapies consist of 5-10 day intravenous NAD+ programs along with IV Glutathione.

 

Please contact us today here at Upstate IV Therapy at 518-720-7674 for more information and to book a treatment program.

TREATMENT & BENEFITS 

Please call us here at Upstate IV Therapy at 518.720.7674 for your consultation regarding  IV therapy and packages.

Request a Consultation